Dyne Therapeutics, Inc. (DYN) · Nov 5, 2026 · Earnings

Dyne Therapeutics earnings miss as 2027 launch spending ramps

Miss — EPS -$1.06 vs approximately -$0.88 consensus

Dyne Therapeutics’ third-quarter earnings missed consensus as launch preparation and late-stage trial costs drove a sharply wider loss, while key 2027 milestones stayed on track.

Dyne is a late-stage clinical biotech moving toward a possible z-rostudirsen launch in Duchenne muscular dystrophy while advancing z-basivarsen toward a potential DM1 filing; the key near-term milestones are the January 21, 2027 FDA action date and ACHIEVE expansion-cohort data expected in Q1 2027. The clinical timeline is largely established rather than newly created here: the one-year ACHIEVE data had already been disclosed in late September, making this release more of an earnings-and-execution checkpoint than a fresh pipeline read.

*December 31, 2025.

The earnings result is a clear miss, but not a change to the pipeline timetable. Diluted EPS of $1.06 in losses was worse than the published consensus of roughly $0.88 in losses, after last quarter’s larger-than-expected loss had already raised scrutiny around spending. The filing attributes the increase to manufacturing for z-rostudirsen and higher costs for the FORZETTO and HARMONIA Phase 3 trials, so the miss reflects an expensive development and launch phase rather than weaker reported drug efficacy. The company reported, “Net loss for the three months ended September 30, 2026 was $193.6 million, or $1.06 per basic and diluted share.”

Spending is rising faster because Dyne is attempting to cross the commercialization gap. R&D increased by about two-thirds and G&A more than doubled, with G&A specifically tied to potential-launch preparation and added headcount. That makes the quarter financially weaker, but the spending is directed at the company’s stated transition from clinical development toward a possible first product launch. The filing says, “The increase in G&A expenses was primarily due to preparation for the potential launch of z-rostudirsen, including an increase in headcount.” 〔0〕

The balance sheet still supports the stated operating plan. Cash, cash equivalents and marketable securities were $1.134 billion at September 30, 2026, and management says that is sufficient to fund operations into Q2 2028. Cash was broadly stable versus year-end despite the widening quarterly loss, so this filing does not introduce an immediate financing issue. The company stated, “The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2026, will be sufficient to fund its operations into the second quarter of 2028.” 〔1〕

The next value-defining events remain regulatory and clinical, not financial. The z-rostudirsen BLA remains under priority review with a January 21, 2027 PDUFA date, while ACHIEVE registrational-expansion data are planned for Q1 2027. Those milestones were already broadly known, so the filing reinforces execution continuity but does not materially improve the evidence for approval or clinical success. The release states, “Dyne’s BLA is under priority review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of January 21, 2027.” 〔2〕

Bottom line: Dyne remains on its late-stage commercialization path, but Q3 showed a larger-than-expected loss as launch and trial spending ramped. The pipeline timetable held; the new information is mainly that execution is costing more ahead of the pivotal 2027 readouts.

What to watch next

FDA action on z-rostudirsen, January 21, 2027

Original filing on SEC EDGAR

More Dyne Therapeutics, Inc. news

• Dyne Therapeutics clinical data show durable DM1 gains, but pooled doses blur proof